THDB(SH:600867) Zheng Quan Shi Bao Wang·2025-07-01 02:16Core Insights - Tonghua Dongbao and Dongfulong have signed a strategic cooperation agreement to collaborate on product development, equipment innovation, process optimization, and commercial cooperation in the diabetes treatment sector [1][2][3] Company Overview - Tonghua Dongbao specializes in diabetes treatment and has a comprehensive product pipeline, including human insulin, glargine insulin, aspart insulin, liraglutide injection, and related medical devices [1] - The company is advancing innovative drugs in other endocrine areas such as weight loss and gout/hyperuricemia, with ongoing research on ultra-rapid insulin, semaglutide, GLP-1/GIP dual receptor agonists, small molecule GLP-1 receptor agonists, URAT1 inhibitors, and XO/URAT1 dual-target inhibitors [1] Strategic Development - The company emphasizes a dual strategy of "independent research and development + external cooperation" to enhance research efficiency and expand its business scope [2] - Tonghua Dongbao's chairman highlighted the commitment to innovation and patient needs, with increased investment in R&D for insulin analogs and GLP-1 receptor agonists [2] Industry Collaboration - Dongfulong provides comprehensive solutions for pharmaceutical companies, with four core divisions and multiple subsidiaries, focusing on drug manufacturing science and equipment [2] - The collaboration between Tonghua Dongbao and Dongfulong aims to integrate resources to advance technology and industry development in diabetes treatment, enhancing the competitiveness of China's pharmaceutical industry [3]